Media About Us


  • 05 June 2013

    S.Fyodorov Eye Microsurgery Complex and NovaMedica Have Signed a Cooperation Agreement on Localizing Innovative Ophthalmic Treatment Technologies in Russia

    S.Fyodorov Eye Microsurgery Complex and NovaMedica Have Signed a Cooperation Agreement on Localizing Innovative Ophthalmic Treatment Technologies in Russia

    BioForward

    S.Fyodorov Eye Microsurgery Complex Federal State Institution and NovaMedica (a pharmaceutical subsidiary of RUSNANO and Domain Associates) have signed an agreement that covers cooperation on localization of innovative ophthalmic products and technologies sourced from around the globe to be developed and produced in Russia.

  • 05 June 2013

    S.Fyodorov Eye Microsurgery Complex and NovaMedica Have Signed a Cooperation Agreement

    S.Fyodorov Eye Microsurgery Complex and NovaMedica Have Signed a Cooperation Agreement

    HeraldOnline.com

    S.Fyodorov Eye Microsurgery Complex Federal State Institution and NovaMedica (a pharmaceutical subsidiary of RUSNANO and Domain Associates) have signed an agreement that covers cooperation on localization of innovative ophthalmic products and technologies sourced from around the globe to be developed and produced in Russia.

  • 05 June 2013

    NovaMedica and S.Fyodorov Eye Microsurgery ComplexHave Signed a Cooperation Agreement on Localizing Innovative Ophthalmic Treatment Technologies in Russia

    NovaMedica and S.Fyodorov Eye Microsurgery ComplexHave Signed a Cooperation Agreement on Localizing Innovative Ophthalmic Treatment Technologies in Russia

    BayBio

    S.Fyodorov Eye Microsurgery Complex Federal State Institution and NovaMedica (a pharmaceutical subsidiary of RUSNANO and Domain Associates) have signed an agreement that covers cooperation on localization of innovative ophthalmic products and technologies sourced from around the globe to be developed and produced in Russia.

  • 28 May 2013

    Prescription drugs with nanotechnology. Americans to build a pharmaceutical plant in Kaluga

    Prescription drugs with nanotechnology. Americans to build a pharmaceutical plant in Kaluga

    Yulia Kostina, Smart News

    NovaMedica, a joint venture of Domain Associates and RusnanoMedInvest, will complement the pharmaceutical cluster in Kaluga region. A projected plant will be specializing in the manufacturing of therapeutics and medicines for kids. The plant’s capacity is 200 Mio tablets and 5 Mio ampules a year.

  • 27 May 2013

    Tablets from Kaluga

    Tablets from Kaluga

    Maria Dranishnikova, Vedomosti

    “NovaMedica, LLC plans to build a plant at the site of Kaluga pharmaceutical cluster”, - told Vladimir Gurdus, Team Drive (project managing company) member of the Board while present at the Russian pharmaceutical forum, organized by Adam Smith Institute.

  • 29 March 2013

    Russian investment vehicle sets sights on innovative drugs

    Russian investment vehicle sets sights on innovative drugs

    Eugene Gerden, Chemistry World

    Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. Rusnano has been ploughing hundreds of millions of dollars into pioneering pharma companies with the aim of growing Russia’s domestic drug production, and making a tidy return by licensing drugs to foreign partners.

  • 04 February 2013

    Russia is becoming a player in global biopharma

    Russia is becoming a player in global biopharma

    Business New Europe (bne)

    A biotechnology revolution is gathering steam in Russia, spurred by state investment programs, a host of cross-border partnerships and a domestic market that international investors find highly attractive. The government is modernizing a decaying healthcare system by building new hospitals and introducing innovative technologies.

  • 20 December 2012

    Russia fund in consortium to back U.S. pharma firms

    Russia fund in consortium to back U.S. pharma firms

    Megan Davies, Reuters

    Russian state technology firm Rusnano, alongside a group of investors, is investing $93 million in three U.S.-based pharmaceutical firms to develop drugs to treat illnesses such as epilepsy, the investors said on Wednesday.

  • 25 July 2012

    Venture capital spurs Russian drug development Ц in California

    Venture capital spurs Russian drug development Ц in California

    Isabel Gorst, FT-Beyondbrics

    When the Kremlin invited a group of US venture capitalists to Russia during the financial crisis, some of the visitors saw as much an opportunity to scout for fresh sources of capital as they did a new place to invest in.

  • 25 July 2012

    Rusnano and Domain Associates announce first joint investment

    Rusnano and Domain Associates announce first joint investment

    Nano werk

    RusnanoMedInvest (RMI, a portfolio company of RUSNANO) and Domain Associates, the Princeton, NJ- and San Diego, CA-based venture capital firm today announced their first investment under a joint agreement reached in March. The two will jointly invest nearly $40 million in San Diego, CA-based, CoDa Therapeutics, a Domain portfolio company, along with current investors GBS Ventures (Melbourne, Australia) and BioPacificVentures (Auckland, NZ).